A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Tofacitinib | CAS 477600-75-2 - Request Quote

Picture of Tofacitinib
SZ CAT No:SZ-T010095
CAS No
477600-75-2
Mol.F.
C16H20N6O
Mol.Wt.
312.4
Inv. Status
In Stock
Rel. CAS No540737-29-9 (citrate salt)
Shipping Condition Room Temperature

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Tofacitinib is chemically 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile. Tofacitinib is supplied with detailed characterization data compliant with regulatory guideline. Tofacitinib can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Tofacitinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

Buy 477600-75-2

Purchase 477600-75-2

Order 477600-75-2

Enquire 477600-75-2

price of 477600-75-2

477600-75-2 Supplier

477600-75-2 Manufacturer

477600-75-2 Exporter

buy high quality Tofacitinib

Purchase Tofacitinib

Tofacitinib suppliers

Tofacitinib manufacturers

Tofacitinib price

Order Tofacitinib

Enquire Tofacitinib

Tofacitinib cost

Tofacitinib Supplier

Tofacitinib Distributor

Tofacitinib for Method Validation

Tofacitinib Reference Standard

Tofacitinib for ANDA Filing

Tofacitinib for Forced Degradation Studies

Tofacitinib Identification Standards

Tofacitinib for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,